血小板
蛋白质亚单位
内皮
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
P-选择素
穗蛋白
Spike(软件开发)
病毒学
2019-20冠状病毒爆发
生物
血小板活化
2019年冠状病毒病(COVID-19)
免疫学
细胞生物学
医学
生物化学
病理
计算机科学
遗传学
传染病(医学专业)
爆发
疾病
软件工程
基因
作者
Cheng Wang,Shaobo Wang,Xiangyu Ma,Xiaohong Yao,Kegang Zhan,Zai Wang,Di He,Wenting Zuo,Songling Han,Gaomei Zhao,Bin Cao,Jinghong Zhao,Xiu‐Wu Bian,Junping Wang
出处
期刊:ACS Infectious Diseases
[American Chemical Society]
日期:2024-06-24
卷期号:10 (8): 2656-2667
标识
DOI:10.1021/acsinfecdis.3c00728
摘要
SARS-CoV-2 infection starts from the association of its spike 1 (S1) subunit with sensitive cells. Vesicular endothelial cells and platelets are among the cell types that bind SARS-CoV-2, but the effectors that mediate viral attachment on the cell membrane have not been fully elucidated. Herein, we show that P-selectin (SELP), a biomarker for endothelial dysfunction and platelet activation, can facilitate the attachment of SARS-CoV-2 S1. Since we observe colocalization of SELP with S1 in the lung tissues of COVID-19 patients, we perform molecular biology experiments on human umbilical vein endothelial cells (HUVECs) to confirm the intermolecular interaction between SELP and S1. SELP overexpression increases S1 recruitment to HUVECs and enhances SARS-CoV-2 spike pseudovirion infection. The opposite results are determined after SELP downregulation. As S1 causes endothelial inflammatory responses in a dose-dependent manner, by activating the interleukin (IL)-17 signaling pathway, SELP-induced S1 recruitment may contribute to the development of a "cytokine storm" after viral infection. Furthermore, SELP also promotes the attachment of S1 to the platelet membrane. Employment of PSI-697, a small inhibitor of SELP, markedly decreases S1 adhesion to both HUVECs and platelets. In addition to the role of membrane SELP in facilitating S1 attachment, we also discover that soluble SELP is a prognostic factor for severe COVID-19 through a meta-analysis. In this study, we identify SELP as an adhesive site for the SARS-CoV-2 S1, thus providing a potential drug target for COVID-19 treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI